Immunai Stock

Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.

Sign up today and learn more about Immunai Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Immunai Stock

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Funding History

May 2020$20.0M
February 2021$60.0M
October 2021$215M

Management

Chief Technology Officer and Co-founder

Luis F Voloch

Scientific Co-founder

Danny Wells

CEO and co-founder

Noam Solomon

Scientific Founder

Ansuman Satpathy

Scientific Founder

Dan Littman

Board Member

Eli Groner

Board Member

Robert Langer

Board memeber

Shahar Tzafrir

Chief Business Officer

Mark Jacobstein

SeniorAdvisor

Michael Aberman

Board Member

Zvika Orron

Board Member

Kenan Turnacioglu

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo